미국 · 보도자료 · IMNM · 2026-09-30 11:45
이뮤놈, 고형암 ADC 신약 후보 'IM-1340' 임상시험계획(IND) 승인
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for the treatme
